A Phase 3 Randomized Double-blind Trial of Maintenance With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer.

Trial Profile

A Phase 3 Randomized Double-blind Trial of Maintenance With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer.

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Jul 2018

At a glance

  • Drugs Niraparib (Primary)
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms NOVA
  • Sponsors TESARO
  • Most Recent Events

    • 16 Jul 2018 Results published in the Lancet Oncology
    • 05 Jun 2018 Results assessing cost-effectiveness of maintenance therapy from GOG 212,, GOG 218, ICON 7, OCEANS, GOG 213, NOVA, SOLO-2 ARIEL-3 and KEYNOTE-028 trials presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 14 May 2018 According to the results published in the Annals of Oncology, retrospective analysis reported to identify clincial parameters to select the optimal individualised dose for a patients with fewer grade less than equal to 3 adverse reactions.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top